Investors

CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 10, 2024-- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) announced that the stockholders at a Special Meeting held today overwhelmingly approved adopting a Plan of Dissolution. Following that announcement, the Board of

CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 9, 2024-- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) today announced that the Board of Directors intends to declare a liquidating cash dividend in the amount of $15.10 per share, if stockholder approval of the Plan of

Company Updates Potential Range of Initial Liquidating Distribution and Additional Dividend Information CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 30, 2024-- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) today announced that it has filed notice with NASDAQ of the